147 related articles for article (PubMed ID: 27446378)
1. Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.
Barranco JA; Millar RP; Fuentes F; Bover E; Pimentel E; Basulto R; Calzada L; Morán R; Rodríguez A; Garay H; Reyes O; Castro MD; Bringas R; Arteaga N; Toudurí H; Rabassa M; Fernández Y; Serradelo A; Hernández E; Guillén GE
Oncol Lett; 2016 Aug; 12(2):963-970. PubMed ID: 27446378
[TBL] [Abstract][Full Text] [Related]
2. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
3. Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma.
Campal-Espinosa AC; Junco-Barranco JA; Fuentes-Aguilar F; Calzada-Aguilera L; Rivacoba-Betancourt A; Rodríguez-Bueno RH; Bover-Campal AC; Bover-Fuentes EE; González L; de Quesada L; Alvarez A; Garay-Pérez HE
Technol Cancer Res Treat; 2023; 22():15330338231207318. PubMed ID: 37828833
[TBL] [Abstract][Full Text] [Related]
4. Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.
Junco JA; Rodríguez R; Fuentes F; Baladrón I; Castro MD; Calzada L; Valenzuela C; Bover E; Pimentel E; Basulto R; Arteaga N; Cid-Arregui A; Sariol F; González L; Porres-Fong L; Medina M; Rodríguez A; Garay AH; Reyes O; López M; de Quesada L; Alvarez A; Martínez C; Marrero M; Molero G; Guerra A; Rosales P; Capote C; Acosta S; Vela I; Arzuaga L; Campal A; Ruiz E; Rubio E; Cedeño P; Sánchez MC; Cardoso P; Morán R; Fernández Y; Campos M; Touduri H; Bacardi D; Feria I; Ramirez A; Cosme K; Saura PL; Quintana M; Muzio V; Bringas R; Ayala M; Mendoza M; Fernández LE; Carr A; Herrera L; Guillén G
Front Oncol; 2019; 9():49. PubMed ID: 30859088
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for control of fertility and hormone dependent cancers.
Talwar GP; Singh O; Pal R; Chatterjee N
Int J Immunopharmacol; 1992 Apr; 14(3):511-4. PubMed ID: 1618603
[TBL] [Abstract][Full Text] [Related]
6. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model.
Hill RE; de Avila DM; Bertrand KP; Greenberg NM; Reeves JJ
Exp Biol Med (Maywood); 2003 Jul; 228(7):818-22. PubMed ID: 12876301
[TBL] [Abstract][Full Text] [Related]
7. The influence of different peptide combinations to increase the immunogenicity of the Gonadotrophin Releasing Hormone Vaccine for prostate cancer treatment.
Aguilar FF; Barranco JJ; Aguilera LC; Fuentes EB; Serradelo Leal JA; López EH; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
J Exp Ther Oncol; 2017 Nov; 12(2):87-94. PubMed ID: 29161775
[TBL] [Abstract][Full Text] [Related]
8. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
9. Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
Triozzi PL; Bolger GB; Neidhart J; Rinehart JJ; Saleh M; Allen KO; Sellers S; Waddell MJ
Prostate; 2005 Dec; 65(4):316-21. PubMed ID: 16015596
[TBL] [Abstract][Full Text] [Related]
10. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
11. Pituitary receptor sites for gonadotropin-releasing hormone: effect of castration and substitutive therapy with sex steroids in the male rat.
Conne BS; Scaglioni S; Lang U; Sizonenko PC; Aubert ML
Endocrinology; 1982 Jan; 110(1):70-9. PubMed ID: 6274626
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of an immunocastration vaccine formulation to reduce the gonadal function in female and male mice by Th1/Th2 immune response.
Siel D; Vidal S; Sevilla R; Paredes R; Carvallo F; Lapierre L; Maino M; Pérez O; Sáenz L
Theriogenology; 2016 Oct; 86(6):1589-1598. PubMed ID: 27344434
[TBL] [Abstract][Full Text] [Related]
13. Anti-fertility vaccines.
Talwar GP; Raghupathy R
Vaccine; 1989 Apr; 7(2):97-101. PubMed ID: 2665354
[TBL] [Abstract][Full Text] [Related]
14. Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.
Pham T; Sadowski MC; Li H; Richard DJ; d'Emden MC; Richard K
Exp Hematol Oncol; 2015; 5():15. PubMed ID: 27340608
[TBL] [Abstract][Full Text] [Related]
15. Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle.
Dar P; Kalaivanan R; Sied N; Mamo B; Kishore S; Suryanarayana VV; Kondabattula G
Vaccine; 2013 Jul; 31(33):3327-32. PubMed ID: 23735678
[TBL] [Abstract][Full Text] [Related]
16. Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
Caballero I; Aira LE; Lavastida A; Popa X; Rivero J; González J; Mesa M; González N; Coba K; Lorenzo-Luaces P; Wilkinson B; Santiesteban Y; Santiesteban Y; Troche M; Suarez E; Crombet T; Sánchez B; Casacó A; Macías A; Mazorra Z
Front Pharmacol; 2017; 8():263. PubMed ID: 28539888
[TBL] [Abstract][Full Text] [Related]
17. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.
Junco JA; Basalto R; Fuentes F; Bover E; Reyes O; Pimentel E; Calzada L; Castro MD; Arteaga N; López Y; Hernández H; Bringas R; Garay H; Peschke P; Bertot J; Guillén G
Adv Exp Med Biol; 2008; 617():581-7. PubMed ID: 18497085
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone/human chorionic gonadotropin beta based recombinant antibodies and vaccines.
Talwar GP; Vyas HK; Purswani S; Gupta JC
J Reprod Immunol; 2009 Dec; 83(1-2):158-63. PubMed ID: 19854518
[TBL] [Abstract][Full Text] [Related]
20. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
